Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928668 | 1.00 | TAAR1 (0.57) | TAAR1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2604881 | 0.85 | SLC6A2 (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL29786276 | 0.85 | SLC6A2 (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL3265767 | 0.82 | CYP2A6 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1245510 | 0.82 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22113733 | 0.82 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL14233502 | 0.82 | NPC1 (0.53) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL23689573 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL21715696 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL22060305 | 0.80 | CFTR (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822265-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer AG (DE) | 2021-05-19 | — | — | EP | disclosed |
| CN-108617166-A | Protein Kinase Inhibitor Benzolactam Compounds | 大冢制药株式会社 | 2018-10-02 | — | — | CN | disclosed |
| EP-2382274-B1 | AQUEOUS COATING COMPOSITION COMPRISING PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN | BASF COATINGS GMBH (DE) | 2015-04-22 | — | — | EP | disclosed |
| CN-102272246-B | Pyridine group-containing electrocoat resin | BASF COATINGS GMBH | 2014-09-17 | — | — | CN | disclosed |
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| CN-102272246-A | Pyridine group-containing electrocoat resin | — | 2011-12-07 | — | — | CN | disclosed |
| EP-2382274-A1 | PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN | BASF Coatings GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| CN-1222909-A | Pyrazinone thrombin inhibitors | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| EP-0094191-B1 | ANTIULCER 2-GUANIDINO-4-(2-SUBSTITUTED-AMINO-4-IMIDAZOLYL)-THIAZOLES AND PROCESS THEREFOR | PFIZER INC. (US) | 1988-04-20 | — | — | EP | disclosed |
| US-4435396-A | FROM 2-AMINO-5-ACETYLOXAZOLE | PFIZER INC. (US) | 1984-03-06 | — | — | US | disclosed |
| EP-0094191-A1 | Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)-thiazoles and process therefor | PFIZER INC. (US) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | TAAR1 112/4885CFTR 288/4885SLC6A2 629/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | TAAR1 112/4885CFTR 288/4885SLC6A2 629/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | TAAR1 126/4885CFTR 319/4885SLC6A2 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.